Blood glucose regulatory pathway

The "Blood glucose regulatory pathway" is not a single molecule or receptor but rather a complex network of physiological processes and molecular interactions that maintain blood glucose levels within a narrow range. This system primarily involves the hormones insulin and glucagon, both produced by the pancreas. Insulin lowers blood glucose by promoting cellular uptake and storage as glycogen or fat when levels are high; glucagon raises blood glucose by stimulating glycogen breakdown and gluconeogenesis in the liver when levels are low[2][4]. Additional components include various enzymes involved in glycolysis, gluconeogenesis, glycogenolysis, and glycogenesis; transporters such as GLUT1–4 for cellular uptake of glucose; and other hormones like somatostatin that modulate insulin/glucagon balance[1][3][4]. Dysregulation of this pathway underlies metabolic diseases such as diabetes mellitus. Note on target status & related fields: This entry is **not** considered a therapeutic target itself—it refers to an entire biological process/pathway rather than a discrete druggable entity like an enzyme or receptor. Drugs used to treat disorders of this system act on specific molecules within the pathway—such as insulin analogs targeting the insulin receptor or SGLT2 inhibitors targeting sodium-glucose cotransporters—but not on "the blood glucose regulatory pathway" as a whole[1][3]. Therefore, fields such as interacting_drugs, mechanism_of_action, biomarkers, and safety_concerns should be populated at the level of individual molecular targets within this system rather than for the overall process. In summary: "Blood glucose regulatory pathways" describes an essential physiological network involving multiple molecules but is not itself a canonical drug target.

Other names

Blood glucose regulationGlucose homeostasisGlucose regulatory pathwayRegulation of blood sugar